<DOC>
	<DOCNO>NCT02059291</DOCNO>
	<brief_summary>ThIS study determine whether canakinumab able induce maintain clinically meaningful reduction disease activity participant Hereditary Periodic Fevers ( HPF ) compare placebo .</brief_summary>
	<brief_title>Study Efficacy Safety Canakinumab Patients With Hereditary Periodic Fevers</brief_title>
	<detailed_description>This study consist 3 randomized cohort ( one per condition colchicine resistant/intolerant Familial Mediterranean Fever ( crFMF ) , Hyper Immunoglobulin D Syndrome ( also know mevalonate kinase deficiency ( HIDS/MKD ) , Tumor Necrosis Factor Receptor Associated Periodic Syndrome ( TRAPS ) , 4 study epoch : 1 . Epoch 1 : screening epoch ass participant 's eligibility ; 2 . Epoch 2 : randomize treatment epoch 16 week participant randomize canakinumab 150 mg every 4 week ( q4w ) placebo obtain efficacy safety data double-blind placebo control parallel-arm setting . This epoch contain 2 possible escape option : 1. early blind escape option non responder Day 8 Day 28 add-on dose 150mg canakinumab follow blinded uptitration next scheduled visit ( Day 29 ) 2. late unblinded escape option non responder Day 29 Day 112 ; open-label uptitration 3 . Epoch 3 : randomize withdrawal epoch 24 week canakinumab responder randomize treatment epoch re-randomized canakinumab 150mg q8w placebo assess potential canakinumab maintain clinical efficacy reduce dosing frequency ; 4 . Epoch 4 : open-label treatment epoch 72 week collect long-term</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Familial Mediterranean Fever</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Hereditary Autoinflammatory Diseases</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patient 's write informed consent ( parent 's write informed consent case pediatric patient ) screen Male female patient least 2 year age time screen visit . Male female patient &gt; 28 day &lt; 2 year eligible open label treatment . Confirmed diagnosis active flare randomization CRP &gt; 10mg/L randomization Use follow therapy ( within vary protocol define timeframes ) : Corticosteroids , anakinra , canakinumab , rilonacept , tocilizumab , TNF inhibitor , abatacept , tofacitinib , rituximab , leflunomide , thalidomide , cyclosporine , intravenous immunoglobulin , 6Merceptopurine , azathioprine , cyclophosphamide , chlorambucil , investigational biologics History malignancy organ system ( localize basal cell carcinoma skin situ cervical cancer ) , treat untreated Significant medical disease , include limited following : . History organ transplantation b. Elevated liver enzymes â‰¥3x ULN d. Increase total bilirubin e. Serious hepatic disorder ( ChildPugh score B C ) f. Chronic Kidney Disease g. Thyroid disease h. Diagnosis active peptic ulcer disease i. Coagulopathy j . Significant CNS effect include vertigo dizziness Any condition significant medical problem immunecompromise patient and/or place patient unacceptable risk immunomodulatory therapy Live vaccination within 3 month prior start trial , trial , 3 month follow last dose</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Canakinumab , interleukin-1 , Hereditary Periodic Fevers , auto-inflammatory disease</keyword>
</DOC>